5.3 Chronic Pulmonary Disorders: Pediatric Asthma & Cystic Fibrosis Management

Chronic Pulmonary Disorders: Pediatric Asthma & Cystic Fibrosis Management

Quick Overview: Chronic pediatric pulmonary disorders require meticulous, longitudinal nursing management, extensive patient-family education, and rapid recognition of acute decompensation. Pediatric asthma—the most prevalent chronic childhood disease—involves reversible airway obstruction, chronic eosinophilic inflammation, and bronchial hyperreactivity governed by structured Asthma Action Plans. Cystic fibrosis (CF), an autosomal recessive multisystem disorder, results in viscous exocrine secretions requiring a disciplined daily routine of sequenced aerosol therapies, airway clearance, pancreatic enzyme replacement, and aggressive nutritional support.

---

1. Pediatric Asthma: Pathophysiology & Diagnostic Criteria

Asthma is a heterogeneous, chronic inflammatory disorder of the conducting airways characterized by three cardinal features: recurrent bronchial smooth muscle spasm, chronic mucosal inflammation with edema, and mucus hypersecretion with plugging, producing variable and reversible airflow limitation.

Cellular Pathophysiology & Airway Remodeling

• Immune Mechanisms: In atopic pediatric asthma, allergen inhalation triggers activation of antigen-presenting cells that prime Type 2 T-helper (Th2) lymphocytes. Th2 cytokines (interleukins IL-4, IL-5, and IL-13) drive B-cell synthesis of immunoglobulin E (IgE), recruit and activate eosinophils, and promote mast cell degranulation.
• Early-Phase Response (within 15–30 minutes): Cross-linking of allergen-specific IgE on sensitized mucosal mast cells causes instantaneous degranulation, releasing pre-formed histamine, leukotrienes (LTC4, LTD4, LTE4), and prostaglandins. These mediators induce acute bronchial smooth muscle contraction, mucosal vasodilation, and vascular leakage.
• Late-Phase Response (4–12 hours later): Influx of activated eosinophils, basophils, and neutrophils propagates sustained mucosal inflammation, epithelial desquamation, and excessive production of thick, tenaceous mucus by hypertrophied goblet cells.
• Airway Remodeling: Chronic, poorly controlled inflammation leads to irreversible structural alterations: subepithelial reticular basement membrane thickening, smooth muscle hypertrophy and hyperplasia, goblet cell metaplasia, and subepithelial fibrosis, resulting in fixed airflow limitation and baseline lung function loss.

Diagnostic Evaluation & Spirometry (Children >= 5 Years)

Spirometry is the gold-standard objective diagnostic modality in children aged 5 years and older (preschool children younger than 5 years are diagnosed primarily on clinical history, recurrent wheezing patterns, and response to therapeutic trials):

1. Baseline Airflow Obstruction: Demonstrated by a reduced Forced Expiratory Volume in 1 second (FEV1) and a reduced FEV1/FVC ratio (< 0.80 to 0.85 in children, or below the lower limit of normal [LLN]).
2. Reversibility Criteria: Following administration of an inhaled short-acting beta-2 agonist (4 puffs of albuterol via spacer), an increase in FEV1 of >= 12% (or an absolute volume increase of >= 200 mL) demonstrates significant bronchodilator reversibility, confirming the diagnosis of asthma.
3. Fractional Exhaled Nitric Oxide (FeNO): An elevated FeNO (> 35 ppb in children) serves as an objective biomarker of active Th2-driven eosinophilic airway inflammation and predicts positive responsiveness to inhaled corticosteroids.

---

2. The Pediatric Asthma Action Plan & Peak Flow Monitoring

Every child with asthma must have an individualized, written Asthma Action Plan developed collaboratively between the healthcare provider, the nurse, and the family. The plan provides objective, actionable instructions for daily maintenance and acute exacerbation management based on symptoms and Peak Expiratory Flow Rate (PEFR).

Peak Flow Arithmetic & Personal Best

• Peak Expiratory Flow Meter: A handheld mechanical device measuring the maximum velocity of airflow generated during a forced expiration starting from total lung capacity.
• Establishing "Personal Best": The child records their PEFR twice daily for 2 to 3 weeks during a period of optimal health and clinical stability. The highest number achieved establishes the "personal best" benchmark (100%) against which all future readings are calculated.

The Three Action Plan Zones

---

3. Pharmacological Classification & Delivery Devices

Pediatric asthma medications are categorized into Relievers (Rescue) and Controllers (Maintenance):

1. Relievers / Rescue Medications (Acute Bronchospasm)

• Short-Acting Beta-2 Agonists (SABA): Albuterol (salbutamol), Levalbuterol (the pure R-enantiomer, associated with slightly less beta-1 tachycardia). Relaxes bronchial smooth muscle via adenylate cyclase activation and cyclic AMP (cAMP) generation within 5 to 15 minutes, lasting 4 to 6 hours. Indicated for acute symptom relief and pre-exercise prevention. Adverse effects: tachycardia, skeletal muscle tremors, transient hypokalemia, restlessness.
• Inhaled Anticholinergics: Ipratropium bromide. Blocks muscarinic cholinergic receptors (M3) on airway smooth muscle, inhibiting acetylcholine-mediated bronchoconstriction and reducing mucus hypersecretion. Added to albuterol during moderate-to-severe acute emergency department exacerbations.

2. Controllers / Long-Term Maintenance Medications (Anti-Inflammatory)

• Inhaled Corticosteroids (ICS): Fluticasone propionate, Budesonide, Beclomethasone dipropionate. The most potent and effective first-line maintenance therapy for persistent asthma across all pediatric ages. Suppresses cytokine production, inhibits eosinophil migration, and upregulates beta-2 receptor expression.
  • Critical Nursing Directive: Instruct the child to rinse their mouth thoroughly with water and spit (or brush teeth) after every ICS inhalation. This prevents drug deposition in the oropharynx, eliminating the risks of oral candidiasis (thrush) and dysphonia.
• Leukotriene Receptor Antagonists (LTRA): Montelukast (Singulair). Oral selective leukotriene D4 (LTD4) receptor antagonist taken once daily in the evening. Highly effective for exercise-induced bronchospasm and allergic rhinitis.
  • FDA Black Box Warning: Montelukast carries a boxed warning for neuropsychiatric events (agitation, aggression, depression, sleep disturbances, vivid nightmares, and suicidal thoughts). Nurses must educate caregivers to immediately discontinue the drug and contact the prescriber if behavioral or mood alterations occur.
• Long-Acting Beta-2 Agonists (LABA): Salmeterol, Formoterol. Provide 12 hours of bronchodilation. Formoterol has a rapid onset of action (1–3 minutes), making it uniquely suited for combination rescue-controller regimens.
  • CRITICAL SAFETY BLACK BOX WARNING: LABAs must NEVER be prescribed as monotherapy in pediatric asthma! Monotherapy does not address underlying inflammation and is associated with severe asthma exacerbations and asthma-related death. LABAs must always be combined with an inhaled corticosteroid in a single combination device (e.g., Fluticasone/Salmeterol [Advair], Budesonide/Formoterol [Symbicort]).
• SMART Regimen (Single Maintenance and Reliever Therapy): National and international asthma guidelines (NAEPP/GINA) now recommend an ICS-formoterol combination inhaler used for both daily maintenance and as-needed rescue relief for children aged 4 to 12+ years with moderate-to-severe persistent asthma, reducing severe exacerbation risk compared to SABA monotherapy rescue.

Inhalation Delivery Devices & Technique

+-------------------------------------------------------------------------+
|                 PEDIATRIC INHALER DEVICE SELECTION                      |
+-------------------------------------------------------------------------+
|  1. MDI WITH VALVED HOLDING CHAMBER (SPACER) & FACE MASK:               |
|     - Age: Infants and children < 4 years of age.                       |
|     - Technique: Secure tight mask seal over nose and mouth; press 1     |
|       puff into chamber; allow child to breathe normally for 5 to 6     |
|       tidal breaths. NEVER administer multiple puffs simultaneously!    |
|                                                                         |
|  2. MDI WITH VALVED HOLDING CHAMBER (SPACER) & MOUTHPIECE:             |
|     - Age: Children 4 years of age and older.                           |
|     - Technique: Exhale completely; place mouthpiece between teeth with |
|       lips sealed; actuate 1 puff; inhale slowly and deeply over 3 to   |
|       5 seconds; hold breath for 10 seconds (or as long as comfortable).|
|                                                                         |
|  3. DRY POWDER INHALERS (DPI - e.g., Diskus, Flexhaler):                |
|     - Age: Children >= 6 to 7 years who can generate rapid, forceful    |
|       inspiratory flow (> 30-60 L/min). Ineffective in acute distress.  |
+-------------------------------------------------------------------------+

---

4. Status Asthmaticus: Emergency Resuscitation & The "Silent Chest"

Status asthmaticus is an acute, severe, life-threatening asthma exacerbation that progresses despite aggressive, repeated administration of inhaled bronchodilators and systemic corticosteroids.

Clinical Presentation & Red Flags

• Severe dyspnea, orthopnea (inability to recline flat), and diaphoresis.
• Monosyllabic speech (inability to speak more than 1 or 2 words between breaths).
• Marked sternocleidomastoid retractions and paradoxical thoracoabdominal ("see-saw") breathing.
• Pulsus Paradoxus: An exaggerated fall in systolic blood pressure of > 10 to 20 mmHg during inspiration, caused by massive intrathoracic pressure swings and ventricular interdependence.

The Ominous "Silent Chest"

In severe asthma exacerbations, high-velocity airflow through narrowed, edematous bronchioles produces loud, turbulent, high-pitched wheezing. When a severely dyspneic child's wheezing suddenly diminishes or completely disappears, and auscultation reveals a "silent chest" with virtually no air entry, this is an OMINOUS SIGN OF IMPENDING RESPIRATORY ARREST.

• The absence of wheezing does not indicate clinical recovery; rather, the airway resistance is so profound, and the child's respiratory muscles are so exhausted, that the child can no longer generate the minimal airflow velocity required to produce a wheeze.
• Hypercapnia (PaCO2 > 42 to 45 mmHg), which is "normal" in an adult, represents severe respiratory failure in a tachypneic child who should be blowing off CO2 (PaCO2 should normally be < 35 mmHg). A "normal" or rising PaCO2 in a tachypneic child signifies severe diaphragmatic fatigue and imminent arrest.

Emergency Pharmacotherapeutic Resuscitation Algorithm

1. Oxygenation: Deliver high-flow humidified O2 via non-rebreather mask to maintain SpO2 >= 94%.
2. Continuous Nebulized Albuterol: Administer albuterol continuously at 10 to 20 mg/hour via high-output nebulizer (or back-to-back treatments of 2.5 to 5 mg every 20 minutes).
3. Inhaled Ipratropium Bromide: Add ipratropium bromide (250 mcg for children < 20 kg; 500 mcg for children >= 20 kg) to the first 3 doses of albuterol.
4. Systemic Corticosteroids: Initiate immediate intravenous Methylprednisolone (1 to 2 mg/kg/day divided every 6 to 12 hours; maximum 60 to 80 mg/day) or oral Dexamethasone/Prednisolone to downregulate inflammatory transcription factors and restore beta-2 adrenergic receptor responsiveness.
5. Intravenous Magnesium Sulfate: Administer Magnesium Sulfate at 25 to 75 mg/kg IV (maximum dose: 2 grams) infused over 20 to 30 minutes. Magnesium competitively antagonizes calcium entry into bronchial smooth muscle cells, inhibits intracellular calcium release from the sarcoplasmic reticulum, and stimulates adenylate cyclase, producing potent smooth muscle relaxation. Continuously monitor blood pressure and deep tendon reflexes during infusion (risk of hypotension and neuromuscular blockade).
6. Subcutaneous / IM Epinephrine or Terbutaline: If severe bronchospasm prevents delivery of nebulized aerosols to the distal airways, activate emergency/critical-care support and follow the prescribed rescue pathway. IM epinephrine is essential when anaphylaxis is suspected; parenteral beta-agonists for refractory asthma require specialist direction rather than routine bedside escalation.
7. Non-Invasive Positive Pressure Ventilation (BiPAP): Provides positive inspiratory and expiratory airway pressure, recruiting collapsed alveoli, unloading fatigued respiratory muscles, and staving off intubation.

---

5. Cystic Fibrosis (CF): Molecular Genetics & Multisystem Pathophysiology

Cystic fibrosis is the most common life-limiting, autosomal recessive genetic disorder among individuals of Caucasian descent, affecting approximately 1 in 3,500 live births.

Molecular Genetics

• Inheritance Pattern: Autosomal recessive. Both parents must be carriers (25% chance of an affected child, 50% chance of an asymptomatic carrier, 25% chance of an unaffected non-carrier child with each pregnancy).
• Gene Locus: Mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene located on the long arm of chromosome 7 (7q31.2).
• The F508del Mutation: The deletion of a single phenylalanine codon at position 508 (Delta F508 or F508del) represents a Class II mutation and accounts for approximately 70% of CF alleles worldwide. It results in misfolding of the CFTR protein, causing it to be targeted for premature degradation in the endoplasmic reticulum before reaching the cell surface.

Multisystem Pathophysiology: The Dehydration Defect

CFTR functions as an apical epithelial cyclic AMP (cAMP)-regulated chloride channel that also tonically inhibits the epithelial sodium channel (ENaC). Defective or absent CFTR produces two distinct physiological defects:

1. In Exocrine Secretory Glands (Lungs, Pancreas, GI Tract): Failure to transport chloride into the lumen is accompanied by hyperactive sodium and water reabsorption back into the epithelial cells. This dehydrates mucosal surfaces, transforming thin, watery secretions into thick, hyperviscous, desiccated secretions that obstruct ducts and tubules.
2. In Sweat Glands: Normal CFTR reabsorbs chloride and sodium from primary sweat as it moves up the duct. In CF, chloride and sodium cannot be reabsorbed, producing excessively salty sweat (NaCl excretion is elevated by 3- to 5-fold).

+-------------------------------------------------------------------------+
|               MULTISYSTEM ORGAN INVOLVEMENT IN CYSTIC FIBROSIS          |
+-------------------------------------------------------------------------+
|  1. PULMONARY: Chronic mucus plugging, impaired mucociliary clearance,   |
|     bacterial colonization (P. aeruginosa), bronchiectasis, cor        |
|     pulmonale, hemoptysis, pneumothorax, and respiratory failure.       |
|                                                                         |
|  2. PANCREATIC (EXOCRINE): Ductal obstruction, acinar cell autolysis,   |
|     fibrosis, complete pancreatic exocrine insufficiency, steatorrhea,  |
|     and severe malabsorption of fats and protein.                       |
|                                                                         |
|  3. PANCREATIC (ENDOCRINE): CF-Related Diabetes (CFRD) secondary to     |
|     islet cell architectural destruction; requires insulin therapy.     |
|                                                                         |
|  4. GASTROINTESTINAL: Meconium ileus in neonates (15-20%), Distal       |
|     Intestinal Obstruction Syndrome (DIOS) in older children, rectal    |
|     prolapse (from chronic bulky stools and straining).                 |
|                                                                         |
|  5. HEPATOBILIARY: Inspissated bile causing focal biliary cirrhosis,    |
|     portal hypertension, esophageal varices, and cholelithiasis.        |
|                                                                         |
|  6. REPRODUCTIVE: Infertility in > 95% of males due to congenital      |
|     bilateral absence of the vas deferens (CBAVD); thick cervical       |
|     mucus causing decreased fertility in females.                       |
+-------------------------------------------------------------------------+

Diagnostic Gold Standard: The Sweat Chloride Test

• Newborn Screening: Universal screening measures immunoreactive trypsinogen (IRT) on dried blood spots. Elevated IRT (secondary to pancreatic duct obstruction spilling trypsinogen into the blood) triggers secondary CFTR DNA mutation testing.
• Quantitative Pilocarpine Iontophoresis (Sweat Test): The definitive gold standard diagnostic test. Pilocarpine is delivered iontophoretically into the skin of the forearm to stimulate localized sweating, and sweat is collected on filter paper or microbore tubing (Macroduct) for at least 30 minutes (minimum 75 mg or 15 mcL of sweat):
  • Normal / CF Unlikely: <= 29 mEq/L (or mmol/L)
  • Intermediate / Borderline: 30 to 59 mEq/L (mandates repeat testing and comprehensive CFTR gene sequencing)
  • Diagnostic of Cystic Fibrosis: >= 60 mEq/L obtained on at least two separate occasions, accompanied by characteristic clinical features or positive family history.

---

6. Comprehensive CF pulmonary management: a prescribed treatment sequence

Pediatric patients with CF battle chronic endobronchial colonization: Staphylococcus aureus and Haemophilus influenzae dominate early infancy, while mucoid Pseudomonas aeruginosa and the multidrug-resistant Burkholderia cepacia complex dominate older childhood and adolescence. Daily airway clearance and sequenced aerosol therapy are vital to prevent irreversible bronchiectasis.

An example treatment sequence to verify with the CF team

To maximize pharmacological deposition and mucus clearance, a commonly used sequence places prescribed bronchodilation and mucus-thinning treatment before airway clearance and inhaled antibiotic afterward; the child's CF team determines which products and timing apply:

+-------------------------------------------------------------------------+
|          THE 5-STEP INHALED SEQUENCE FOR CYSTIC FIBROSIS                |
+-------------------------------------------------------------------------+
|  STEP 1: INHALED BRONCHODILATOR (Albuterol)                             |
|  - Action: Dilates bronchial smooth muscle; opens constricted airways;   |
|    prevents bronchospasm caused by subsequent hypertonic agents.         |
|                                                                         |
|  STEP 2: NEBULIZED HYPERTONIC SALINE (3% or 7% NaCl)                    |
|  - Action: Osmotically draws water from submucosa into airway lumen,     |
|    rehydrating the dehydrated periciliary liquid layer and thinning     |
|    mucus secretions.                                                    |
|                                                                         |
|  STEP 3: NEBULIZED DORNASE ALFA (Pulmozyme / recombinant human DNase)   |
|  - Action: Selectively cleaves long extracellular DNA chains released by |
|    degenerating neutrophils, dramatically reducing sputum viscosity.    |
|  - Storage: MUST be refrigerated (2°C-8°C) and protected from light!    |
|                                                                         |
|  STEP 4: AIRWAY CLEARANCE THERAPY (ACT)                                 |
|  - Modalities: High-Frequency Chest Wall Oscillation (HFCWO / Vest),     |
|    Positive Expiratory Pressure (PEP) mask, or manual percussion.        |
|  - Action: Mechanically loosens and shears thinned mucus, propelling    |
|    secretions toward central airways to be expectorated via huff cough. |
|                                                                         |
|  STEP 5: INHALED ANTIMICROBIAL (Tobramycin, Aztreonam, Colistin)        |
|  - Action: Delivers high topical bactericidal drug concentrations to    |
|    suppress Pseudomonas aeruginosa colonization.                        |
|  - Timing: Administered LAST so medication deposits onto cleanly        |
|    evacuated bronchiolar surfaces rather than being coughed out.        |
+-------------------------------------------------------------------------+

---

7. Gastrointestinal, Pancreatic & Nutritional Management in CF

Over 85% to 90% of children with cystic fibrosis exhibit pancreatic exocrine insufficiency. Without pancreatic enzymes reaching the duodenum, ingested lipids and proteins are lost in the stool, producing severe malnutrition, growth failure, and fat-soluble vitamin deficiency.

Pancreatic Enzyme Replacement Therapy (PERT)

PERT formulations (e.g., Creon, Zenpep, Pancreaze) contain porcine-derived pancrelipase, a balanced mixture of lipase, protease, and amylase.

Dosing Guidelines & Safety Ceilings

• Dosing is customized based on the patient's weight and dietary fat intake.
• Initial starting dose: Typically 500 to 1,000 lipase units/kg/meal (snacks receive half of the meal dose).
• Titrate dose according to stool frequency and consistency (aiming for 1 to 2 formed, non-greasy stools per day) and normal weight velocity.
• CRITICAL SAFETY CEILING: Never exceed 2,500 lipase units/kg per meal or 10,000 lipase units/kg per day! High doses exceeding this ceiling are directly associated with fibrosing colonopathy, a life-threatening complication characterized by severe colonic mucosal ulceration, subepithelial fibrosis, and strictures requiring surgical resection.

Administration Rules for Certified Pediatric Nurses

1. Timing: Enzymes must be consumed immediately before or with the first bites of ALL meals, snacks, and milk/formula feedings. Taking enzymes after eating renders them ineffective because food empties into the duodenum ahead of the enzymes.
2. Handling the Capsules: Older children swallow capsules whole. In infants and young children who cannot swallow pills, the capsule is opened, and the small enteric-coated microspheres/beads are sprinkled onto a small spoonful of acidic, soft food that does not require chewing (such as applesauce, pureed pears, or applesauce-based baby food).
3. DO NOT CRUSH OR CHEW: Instruct parents and children never to crush or chew the enzyme beads. Chewing destroys the protective enteric coating, causing premature enzyme activation in the mouth that produces excruciating oral mucosal ulcerations, while gastric acid destroys the unprotected enzymes in the stomach.
4. AVOID ALKALINE FOODS: Never mix enzyme beads with alkaline or dairy products (such as milk, formula, yogurt, or pudding), as alkaline pH dissolves the enteric coating prematurely.
5. Oral Hygiene: Following administration, inspect the infant's mouth, wipe their lips, and rinse their mouth with water to ensure no residual enzyme beads remain lodged against oral mucosa.

Nutritional Architecture & Vitamin Supplementation

• High-Calorie, High-Protein, Unrestricted Fat Diet: Children with CF require 110% to 200% of the standard Recommended Daily Allowance (RDA) for calories to compensate for malabsorption, chronic pulmonary infection, and increased work of breathing. Dietary fat should never be restricted; whole milk, heavy cream, butter, and calorie-dense nutritional supplements are encouraged.
• Fat-Soluble Vitamin Supplementation (Vitamins A, D, E, K): Because fat malabsorption impairs absorption of lipid-soluble vitamins, children must take daily customized CF-specific multivitamin preparations (e.g., AquADEKs). These formulations present vitamins A, D, E, and K in a water-miscible (water-soluble) form that can be absorbed directly through the intestinal mucosa without requiring bile salts or pancreatic lipase.
• Salt Supplementation: Because CF patients lose excessive sodium and chloride in their sweat, infants require 1/8 to 1/4 teaspoon of supplemental table salt (NaCl) added to daily feeds. Older children require supplemental salt and sports rehydration drinks during hot weather, fever, or vigorous exercise to prevent acute hyponatremic, hypochloremic dehydration.

Meconium Ileus & DIOS

• Meconium Ileus: The earliest clinical presentation of CF, occurring in 15% to 20% of affected neonates. The terminal ileum becomes completely obstructed by thick, tenacious, rubbery, inspissated meconium. Neonates present within the first 24 to 48 hours of life with failure to pass meconium, progressive abdominal distension, and bilious vomiting. An abdominal radiograph shows a "soap bubble" or "ground glass" appearance (Neuhauser sign) in the right lower quadrant, and a diagnostic/therapeutic water-soluble contrast enema (Gastrografin) demonstrates a classic diminutive "microcolon" distal to the obstruction.
• Distal Intestinal Obstruction Syndrome (DIOS): In older children and adolescents with CF, incomplete digestion and thick intestinal secretions cause recurrent partial or complete fecal impaction at the ileocecal junction. Symptoms include crampy right lower quadrant abdominal pain, nausea, and a palpable right lower quadrant mass. DIOS is managed with aggressive oral balanced polyethylene glycol (PEG) electrolyte lavage solutions or water-soluble contrast enemas; surgical intervention is avoided whenever possible.

CFTR Modulator Therapies (Targeted Molecular Therapy)

Modern CF management has been transformed by small-molecule CFTR modulators that treat the underlying protein defect:

• Potentiators (Ivacaftor [Kalydeco]): Binds to defective CFTR channels at the cell surface, holding the channel gate open to facilitate chloride transport (effective for gating mutations such as G551D).
• Correctors (Lumacaftor, Tezacaftor, Elexacaftor): Assist in proper folding of mutated CFTR protein (such as F508del), preventing premature endoplasmic reticulum degradation and facilitating protein trafficking to the cell surface.
• Triple-Combination Therapy (Elexacaftor / Tezacaftor / Ivacaftor [Trikafta]): Two correctors combined with a potentiator, approved for patients with at least one F508del mutation. This regimen dramatically improves lung function (FEV1 increases by 10–14%), decreases sweat chloride levels, reduces pulmonary exacerbations by over 60%, and improves BMI.

CF regimen safeguard: Follow the child's CF center plan for the sequence and timing of bronchodilator, hypertonic saline, dornase alfa, airway clearance, and inhaled antibiotics. There is no universal requirement that every child receive all five in one fixed order. Nutrition and enzyme needs also require individualized reassessment, particularly when highly effective modulator therapy changes growth or nutritional status.

Cystic Fibrosis Foundation mucus-thinning and airway-clearance instructions, checked October 18, 2026.